• In late June 2026, AbbVie reported multiple product wins, including new pediatric approvals for SKYRIZI, positive CHMP opinions for RINVOQ in alopecia areata and non-segmental vitiligo, and strong Phase 3 lymphoma data for epcoritamab plus lenalidomide versus R-GemOx.
• Together, these updates extend AbbVie’s immunology and oncology reach into earlier-stage, high-need patient groups, potentially deepening usage of its existing flagship therapies rather than relying solely on entirely new products.
• We’ll now examine how the CHMP’s positive opinions on RINVOQ for alopecia areata and vitiligo could reshape AbbVie’s investment narrative.

Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

AbbVie Investment Narrative Recap

To own AbbVie, you need to believe its immunology and oncology franchises can offset patent headwinds while it manages debt, pricing pressure, and aesthetics volatility. The latest RINVOQ and SKYRIZI updates support the near term growth story, but the congressional inquiry into China trials and reimbursement shifts remain key watchpoints rather than thesis changers right now.

Among the recent announcements, the CHMP’s positive opinions for RINVOQ in alopecia areata and non segmental vitiligo look most relevant, because they reinforce AbbVie’s effort to deepen use of a core immunology asset across more indications and age groups, which directly relates to how resilient Skyrizi and Rinvoq can be as future competition, pricing pressure, and patent expirations emerge.

Yet even as RINVOQ expands into new indications, investors should be aware that...

AbbVie's narrative projects $79.0 billion revenue and $22.7 billion earnings by 2029. This requires 7.9% yearly revenue growth and an earnings increase of about $19.1 billion from $3.6 billion today.

Uncover how AbbVie's forecasts yield a $253.55 fair value, a 3% downside to its current price.

Exploring Other Perspectives

Three members of the Simply Wall St Community currently see AbbVie’s fair value between US$253.55 and US$457.40 per share, underscoring how far apart individual expectations can be. Against that diversity of views, the central question many are wrestling with is how much weight to place on AbbVie’s expanding RINVOQ and SKYRIZI indications as potential offsets to its concentrated product risk over time.

Explore 3 other fair value estimates on AbbVie - why the stock might be worth as much as 75% more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your AbbVie research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free AbbVie research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate AbbVie's overall financial health at a glance.

Contemplating Other Strategies?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Find 44 companies with promising cash flow potential yet trading below their fair value.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.